contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
      id
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    pageUrl
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


agreement-at-a-value-of-8-msek-signed-between-c-rad-and-new-customer-in-germany

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

C-Rad operates in the medical technology industry and focuses on the development and manufacture of systems for radiation therapy of cancer. The company's products are aimed at healthcare institutions and oncologists. The business is present on a global level, with a main presence in Europe, North America and Asia. C-Rad was founded in 2004 and is headquartered in Uppsala, Sweden.

C-Rad

C-RAD and a new customer in North Rhine-Westphalia, Germany, signed partnership agreement.The order, which has a value, before taxes, of approximately 8.2 MSEK for C-RAD, includes SGRT-solution...

<div class="mfn-preamble"><p><strong>C-RAD and a new customer in North Rhine-Westphalia, Germany, signed partnership agreement.</strong></p></div><div class="mfn-body"><p>The order, which has a value, before taxes, of approximately 8.2 MSEK for C-RAD, includes SGRT-solution for CT room and treatment rooms, including modules for Respiratory Gating, Patient Setup &amp; Positioning, and Motion Monitoring. A service contract for several systems is also included. Delivery and installation are expected to commence before the end of the year.</p><p>“We are honored that this maximum care hospital, with a long and prominent tradition, has selected C-RAD as their preferred solution. We are delighted that this institution decided to incorporate our cutting-edge technology and its clinical benefits into their daily routine, further solidifying our position as market leaders. The installation will be integrated into existing therapy systems, allowing patients and users to experience the benefits of our solution in the near term”, said Cecilia de Leeuw, CEO and President of C-RAD AB.</p></div><div class="mfn-footer mfn-contacts mfn-e520b92ae86a"><p><strong class="mfn-heading-1">For further information:</strong></p><hr><p>Cecilia de Leeuw, CEO, +46 (0)795 85 66 77, <a rel="noopener" href="mailto:investors@c-rad.com">investors@c-rad.com</a><br>Christoffer Herou, CFO, +46 (0)725 82 86 16, <a rel="noopener" href="mailto:investors@c-rad.com">investors@c-rad.com</a></p></div><div class="mfn-footer mfn-about mfn-1fc3b360975a"><p><strong class="mfn-heading-1">About C-RAD</strong></p><hr><p>C-RAD develops surface-guided imaging solutions for radiation therapy to allow highly accurate dose delivery to the tumor, and at the same time, to protect healthy tissue from unwanted exposure. Using high-speed 3D cameras combined with augmented reality, C-RAD supports the initial patient setup process and monitors the patient's motion during treatment to ensure high confidence, an efficient workflow, and improved accuracy. C-RAD monitors the patient's motion without the use of tattoos or additional imaging dose, to deliver the highest level of patient safety and comfort.</p><p>C-RAD. Inspiring excellence in cancer treatment.</p><p>C-RAD AB is listed on NASDAQ Stockholm.</p><p>For more information on C-RAD, please visit&nbsp;<a rel="noopener" href="http://www.c-rad.com/">http://www.c-rad.com</a></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/aed2acb6-7e99-4b14-90b2-7d3355d7c12d/agreement-at-a-value-of-8-msek-signed-between-c-rad-and-new-customer-in-germany.pdf" class="mfn-generated mfn-primary">Agreement at a value of 8 MSEK signed between C-RAD and new customer in Germany</a></p></div>